David N. Stephens – författare
Visar alla böcker från författaren David N. Stephens. Handla med fri frakt och snabb leverans.
2 produkter
2 produkter
E-bok
PDF, Engelska, 20131 408 kr
Läs direkt efter köp
Since the discovery some 15 years ago of benzodiazepinemodulatory sites associated with GABA A receptors, greateffort has gone into understanding their molecularpharmacology and into developing new anxiolytic drugs thatinteract selectively with them. Prominent in this researchhas beenthe discovery that ~-carbolines, a differentchemical class from benzodiazepines, also act at thesereceptors but that their effects are sometimes quitedifferent from those of the benzodiazepines.This bookdocuments the latest discoveries in the molecularbiology of the GABA A receptor and reveals howan integration of the results of research inmolecularbiology, synthetic chemistry, biochemical and behavioralpharmacology, and clinical pharmacology has paved the wayforthe development of ~-carbolines from substances inducinganxiety and convulsions to a novel therapy for anxietystates, achieving a behavioral selectivity through selectiveactions at subtypes of receptors.
Häftad, Engelska, 2011
1 122 kr
Skickas inom 10-15 vardagar
Since the discovery some 15 years ago of benzodiazepinemodulatory sites associated with GABA A receptors, greateffort has gone into understanding their molecularpharmacology and into developing new anxiolytic drugs thatinteract selectively with them. Prominent in this researchhas beenthe discovery that ~-carbolines, a differentchemical class from benzodiazepines, also act at thesereceptors but that their effects are sometimes quitedifferent from those of the benzodiazepines.This bookdocuments the latest discoveries in the molecularbiology of the GABA A receptor and reveals howan integration of the results of research inmolecularbiology, synthetic chemistry, biochemical and behavioralpharmacology, and clinical pharmacology has paved the wayforthe development of ~-carbolines from substances inducinganxiety and convulsions to a novel therapy for anxietystates, achieving a behavioral selectivity through selectiveactions at subtypes of receptors.